Idorsia aims to be Europe’s leading biopharmaceutical company, with a strong scientific core. We provide regular updates on the progress being made towards this goal. This section of the website provides journalists with additional material to support the generation of articles.

About Idorsia

Idorsia Ltd is reaching out for more – We have more ideas, we see more opportunities and we want to help more patients. In order to achieve this, we will develop Idorsia into a leading biopharmaceutical company, with a strong scientific core.

Headquartered near Basel, Switzerland – a European biotech-hub – Idorsia is specialized in the discovery, development and commercialization of small molecules to transform the horizon of therapeutic options. Idorsia has a 20-year heritage of drug discovery, a broad portfolio of innovative drugs in the pipeline, an experienced team of professionals covering all disciplines from bench to bedside, and commercial operations in Europe and North America – the ideal constellation for bringing innovative medicines to patients.

Idorsia was listed on the SIX Swiss Exchange (ticker symbol: IDIA) in June 2017 and has over 800 highly qualified specialists dedicated to realizing our ambitious targets.

Events

Event When

Full-Year 2023 and First Quarter 2024 Financial Results reporting*

April 25, 2024

Annual General Meeting of Shareholders

June 13, 2024

Half Year 2024 Financial Reporting*

July 25, 2024

*We will be in a silent period for 10 days ahead of the financial reporting.

Stay informed

Idorsia offers an electronic ‘Stay Informed’ service where subscribers can automatically receive updates via e-mail or SMS alert.

Social media

Idorsia is active on social media – follow our channels to get a more personal view on the company.

Media center

Checkout the multi-media material we have to support your coverage.